Official releases issued by the company.https://www.adaptogenicscorp.comhttps://www.adaptogenicscorp.com/news/adaptogenics-announces-strategy-to-build-proprietary-peptide-assets-and-delivery-technologieshttps://www.adaptogenicscorp.com/news/adaptogenics-announces-strategy-to-build-proprietary-peptide-assets-and-delivery-technologiesAdaptogenics announced a strategy to build proprietary peptide and small molecule assets through molecular design, selective acquisitions and exclusive licensing. The strategy combines advanced delivery research, planned sourcing from qualified GMP manufacturers and independent quality testing, with an initial focus on metabolic health, muscle preservation and mitochondrial biology. Programs will be guided by measurable development milestones and opportunities to establish defensible intellectual property.Mon, 19 Oct 2026 00:00:00 GMThttps://www.adaptogenicscorp.com/news/adaptogenics-appoints-antoun-nabhan-as-presidenthttps://www.adaptogenicscorp.com/news/adaptogenics-appoints-antoun-nabhan-as-presidentAdaptogenics appointed Antoun Nabhan, J.D., as President, bringing nearly 20 years of healthcare investment, corporate finance and business development experience. He has led or advised on more than $2 billion in healthcare transactions and led two Nasdaq IPO processes, with previous roles at Oaktree Capital Management, Onyx Pharmaceuticals and Raptor Pharmaceuticals. Working alongside CEO Dr. J. David Warren, he will lead asset acquisitions, licensing partnerships and strategic collaborations.Tue, 13 Oct 2026 00:00:00 GMThttps://www.adaptogenicscorp.com/news/adaptogenics-acquires-nutritional-research-assets-to-advance-glp-1-companion-initiativehttps://www.adaptogenicscorp.com/news/adaptogenics-acquires-nutritional-research-assets-to-advance-glp-1-companion-initiativeAdaptogenics acquired nutritional research assets developed by Berkwood Research to support its GLP-1 companion initiative, focused on muscle preservation, metabolic health and physical function during medical weight loss. The acquisition includes four research compositions and 36 ingredient evidence reviews, providing a foundation for product selection and further testing. Dr. Robert Bergia, formerly a leader in protein nutrition research at ADM, joins as Scientific Advisor. Effectiveness in patients receiving GLP-1 therapies remains to be established.Thu, 08 Oct 2026 00:00:00 GMThttps://www.adaptogenicscorp.com/news/adaptogenics-appoints-accomplished-peptide-scientist-dr-j-david-warren-as-chief-executive-officerhttps://www.adaptogenicscorp.com/news/adaptogenics-appoints-accomplished-peptide-scientist-dr-j-david-warren-as-chief-executive-officerAdaptogenics appointed Dr. J. David Warren as CEO and Director, bringing more than 20 years of experience in peptide science, medicinal chemistry and drug discovery. His credentials include 17 issued patents, more than 53 publications and book chapters, and foundational research on SS 31, now known as elamipretide and subsequently approved by the FDA as Forzinity. He will lead the evaluation and development of proprietary peptide and small molecule candidates.Mon, 05 Oct 2026 00:00:00 GMT